USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
WOOMERA THERAPEUTICS, INC.
Address:
115 ETNA RD, STE D
LEBANON, NH
Phone:
N/A
URL:
N/A
EIN:
137147015
DUNS:
149245123
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $200,001.00 2
SBIR Phase II $1,674,892.00 2

Award List:

MAG-1 Targeting of GRSA on Breast Cancer

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to utilize different forms of a mouse monoclonal antibody, mMAG-1, not only to direct successful imaging of breast cancer but also to develop more rational approaches to treatment. The hypothesis being tested is that… More

Treatment of Breast Cancer with MAG-1 Antibody

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$688,433.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to utilize a monoclonal antibody, MAG-1, to develop new, rational, and successful treatment of breast cancer. The hypothesis being tested is that Glycopeptide-Related cell-Surface Antige n (GRSA) will provide a sensitive and… More

Targeted Treatment of Recurrent Small Cell Lung Cancer with Anti-AbnV2 Antibodies

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$100,001.00
Agency:
HHS
Principal Investigator:
Roy H. Pang – 603-448-5511
Abstract:
DESCRIPTION (provided by applicant): The objective of this Phase 1 project is to improve an effective treatment of recurrent small-cell lung cancer (rSCLC) by targeting a tumor-specific abnormal receptor, AbnV2 that is a surface-marker of the disease. Currently, there is no effective treatment for… More

Targeted Treatment of Recurrent Small Cell Lung Cancer with Anti-AbnV2 Antibodies

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$986,459.00
Agency:
HHS
Principal Investigator:
Roy H. Pang – 603-448-5511
Abstract:
DESCRIPTION (provided by applicant): There is currently no effective treatment for recurrent small-cell lung cancer (rSCLC). The objective of this project is to utilize a monoclonal antibody, Abner, to develop new, rational, and successful treatment of rSCLC. The hypothesis being tested is that an… More